Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0T1UJ
|
|||
| Former ID |
DAP001195
|
|||
| Drug Name |
Reteplase
|
|||
| Synonyms |
Retevase; Rapilysin (TN); Retavase (TN); Retevase (TN); Reteplase (USAN/INN)
Click to Show/Hide
|
|||
| Indication | Heart attack [ICD-11: BA41; ICD-9: 410] | Approved | [1], [2] | |
| Therapeutic Class |
Thrombolytic Agents
|
|||
| PubChem Substance ID | ||||
| ADReCS Drug ID | BADD_D01929 | |||
| SuperDrug ATC ID |
B01AD07
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. | |||
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 3 | Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23. | |||
| REF 4 | Spotlight on reteplase in thrombotic occlusive disorders. BioDrugs. 2007;21(1):65-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.